English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT05002569 /

CA224-098

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma

DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase III
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: